Background Single inhaler triple therapies providing an inhaled corticosteroid, a long-acting
muscarinic antagonist, and a long-acting β 2-agonist (ICS/LAMA/LABAs) are an emerging …

Background Evidence is scarce on the relative risk-benefit of inhaled triple therapy,
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β 2 …

Background The comparative efficacy of inhaled corticosteroid/long-acting muscarinic
antagonist/long-acting β 2-agonist (ICS/LAMA/LABA) triple therapy administered via single …

Although pharmacological treatment of COPD is codified in different guidelines and strategy
documents, there is abundant evidence of discrepancy between what they suggest and what …

Patients with symptomatic advanced chronic obstructive pulmonary disease (COPD) who
experience recurrent exacerbations are particularly at risk of poor outcomes and present a …

Purpose Treatment guidance for chronic obstructive pulmonary disease (COPD)
recommends inhaled corticosteroid (ICS)+ long-acting muscarinic antagonist+ long-acting …

Background Few data are available for the efficacy of" triple therapy" with two long-acting
bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease …

Background: Various combinations of inhaled corticosteroid (ICS), long-acting muscarinic
antagonist (LAMA), and long-acting beta-agonist (LABA) have been used as triple therapy …

Background Previous studies have highlighted a relationship between reduction in rate of
exacerbations with therapies containing inhaled corticosteroids (ICS) and baseline blood …

Pharmacological treatment for chronic obstructive pulmonary disease (COPD) aims to
alleviate symptoms and reduce the future risk of events such as exacerbations, disease …